Biotech | February 27, 2022
New data reinforces efficacy of Tezspire
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
The facility is spread across 215000 sq. feet and provides super-speciality care
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
New biotechnology product aims to be world's fastest automatic sanitary solution
Subscribe To Our Newsletter & Stay Updated
